drugset
drugset / Trial / NCT04175132

Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

NCT04175132 ↗

Phase 1 Terminated 6 enrolled H. Lundbeck A/S
Non-randomizedSequentialOpen-labelTreatment

Summary

A study to learn how foliglurax binds in regions of the brain

Timeline

Start
2019-11-12
Primary completion
2020-03-03
Completion
2020-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Foliglurax Small molecule 20 mg Oral
Subject Foliglurax Small molecule 80 mg Oral
Subject Foliglurax Small molecule 160 mg Oral
Subject Foliglurax Small molecule 240 mg Oral

Indications

Parkinson disease